GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives $8.38 Consensus Target Price from Analysts

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) have been assigned a consensus recommendation of “Moderate Buy” from the fifteen research firms that are covering the company, MarketBeat reports. Five investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $8.38.

Several brokerages have weighed in on GDRX. KeyCorp lowered their target price on shares of GoodRx from $7.00 to $6.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Morgan Stanley lowered their target price on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 17th. Citigroup lowered their target price on shares of GoodRx from $7.00 to $6.25 and set a “buy” rating for the company in a research note on Friday, January 10th. Mizuho started coverage on shares of GoodRx in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 target price for the company. Finally, Barclays lowered their price objective on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a research note on Monday, November 11th.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Fortem Financial Group LLC purchased a new position in shares of GoodRx during the third quarter worth $772,000. Barclays PLC increased its holdings in GoodRx by 1,316.1% in the third quarter. Barclays PLC now owns 140,113 shares of the company’s stock valued at $973,000 after buying an additional 130,219 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in GoodRx by 5.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 480,123 shares of the company’s stock valued at $3,332,000 after buying an additional 26,262 shares in the last quarter. Raymond James & Associates increased its holdings in GoodRx by 212.6% in the third quarter. Raymond James & Associates now owns 394,006 shares of the company’s stock valued at $2,734,000 after buying an additional 267,951 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd increased its holdings in GoodRx by 260.7% in the third quarter. Dynamic Technology Lab Private Ltd now owns 44,419 shares of the company’s stock valued at $308,000 after buying an additional 32,104 shares in the last quarter. Hedge funds and other institutional investors own 63.77% of the company’s stock.

GoodRx Price Performance

Shares of GDRX opened at $4.71 on Thursday. The company has a market cap of $1.80 billion, a price-to-earnings ratio of -157.00, a price-to-earnings-growth ratio of 2.31 and a beta of 1.27. GoodRx has a twelve month low of $4.09 and a twelve month high of $9.26. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. The company has a 50 day moving average of $4.59 and a two-hundred day moving average of $6.39.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.